AI in Pharma: Transforming Drug Discovery and Strategic Management with MYC-Modulating Compounds and BET Protein Inhibitors.
Robert B KargboPublished in: ACS medicinal chemistry letters (2024)
The landscape of pharmaceutical R&D is being reshaped by the synergistic integration of Artificial Intelligence (AI) and groundbreaking drug discoveries, mainly focusing on MYC-modulating compounds and BET protein inhibitors. This Patent Highlight delves into this convergence, illustrating a transformative shift in the pharmaceutical industry's approach to drug development, strategic management, and treating various diseases, from cancer to inflammatory and fibrotic disorders.
Keyphrases
- artificial intelligence
- drug discovery
- machine learning
- big data
- deep learning
- transcription factor
- signaling pathway
- protein protein
- papillary thyroid
- oxidative stress
- binding protein
- systemic sclerosis
- squamous cell carcinoma
- amino acid
- squamous cell
- small molecule
- idiopathic pulmonary fibrosis
- single cell
- emergency department
- young adults
- adverse drug